Polymorphisms In ERCC1, RRM1 Genes And Sensitivity To Gemcitabine /cisplatin Chemotherapy In Advanced Non-small Cell Lung Cancer

Purpose To investigate the relationship between genetic polymorphisms in excision repair cross complementation group 1 ( ERCC1) 118 and ribonucleotide reductase M1(RRM1)37 and the response to gemcitabine/ cisplatin( GP regimen ) chemotherapy in advanced non-small cell lung cancer(NSCLC)..Materials and Methods Sixty patients with advanced NSCLC were analyzed. All the patients were treated with GP regimen chemotherapy and their DNA of peripheral blood leukocytes was obtained before the therapy. ERCC1 and RRM1 genotypes were detected by the PCR-LDR method.Results 1) Of all the cases, the frequencies of ERCC1 118 C/ C , C/ T and T/ T genotypes were 56.7 % , 38.3 % and 5.0 % , respectively , while the frequencies of RRM1 37 C/ C, C/A and A/A genotypes were 48.3 % , 36.7 % and 15.0 % , respectively. The overal response rate to chemotherapy in all of the patients was 38.3 %. 2) The response rate to therapy among the patients with ERCC1 118 C/C ,C/T and T/T genotypes were 47.1 % ,26.9 % and 0 , respectively , with a statistically significant difference (χ2 = 5.549 , P = 0.018);and the response rate to therapy among the patients with RRM1 37 C/ C, C/ A and A/ A genotypes were 41.4 % ,36.4 % and 33.3 % , respectively. There was no statistically significant difference among three RRM1 37 genotypes (χ2 = 0.246, P = 0.884).Conclusion The polymorphisms of the ERCC1 118 is associated with the clinical response to GP regimen chemotherapy in advanced NSCLC,suggesting the ERCC1 118 genotypes can identify advanced NSCLC patients that will be responsive to GP regimen chemotherapy.